Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2023-09-05 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer
Regulatory Filings Classification · 100% confidence The document is a press release announcing a significant corporate event: the FDA approval of an Investigational New Drug (IND) application for a clinical trial (VB-C-04) involving their therapeutic cancer vaccine candidate (VB10.16). This type of announcement, detailing clinical progress, regulatory milestones, and future plans (like the upcoming Capital Markets Day), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about clinical development and regulatory status, it fits best under the 'Earnings Release' category if it were a quarterly update, but as a standalone, material, non-financial-result-focused announcement, it is most appropriately classified as a general Regulatory Filing (RNS), which serves as the fallback for significant corporate news that isn't a formal financial report (10-K, IR, ER) or a specific transaction notice (CAP, DIV, SHA). Given the content is a direct announcement of a regulatory milestone, RNS is the most suitable general category.
2023-09-05 English
Nykode Therapeutics - Quarterly report Q2 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled '2ND QUARTER 2023 INTERIM REPORT' and contains comprehensive financial statements, including income statements, balance sheets, and cash flow analysis for the period ending June 30, 2023. It provides detailed management commentary on financial results and R&D updates. As it is a full interim financial report rather than a short announcement or a certification, it is classified as an Interim/Quarterly Report. Q2 2023
2023-08-23 English
Nykode Therapeutics - Quarterly report Q2 2023
Report Publication Announcement Classification · 100% confidence The document is a short announcement (approx. 2,800 characters) regarding the release of the Q2 2023 financial results. It does not contain the actual financial statements or substantive financial data, but rather provides a link to the company's website where the report can be accessed. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). Q2 2023
2023-08-23 English
Nykode Therapeutics to announce financial results for the second quarter 2023 and host webcast presentation on August 23, 2023
Report Publication Announcement Classification · 98% confidence The document is a short press release dated August 17, 2023, announcing that Nykode Therapeutics will report its financial results for the second quarter of 2023 on August 23, 2023, and will host a webcast presentation. It does not contain the actual financial results or the full report. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or presented, often providing a link to where it will be found, classifies as a Report Publication Announcement (RPA).
2023-08-17 English
Grant of share options
Director's Dealing Classification · 100% confidence The document text details transactions conducted by persons discharging managerial responsibilities (Michael Engsig, Harald Gurvin, Agnete B. Fredriksen) at Nykode Therapeutics ASA. Specifically, it reports the 'Grant of share options as part of remuneration package' for several executives. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns insider transactions.
2023-07-07 English
Grant of share options
Share Issue/Capital Change Classification · 95% confidence The document text is very short (486 characters) and announces the 'Grant of share options' to employees, specifically mentioning that 'primary insiders' received options. It concludes with 'Please see further details in attached document.' This structure—a brief announcement pointing to an attachment for full details—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content specifically relates to insider transactions/share grants, it is closely related to Director's Dealing (DIRS) or Share Issue/Capital Change (SHA). However, given the brevity and the instruction to classify short announcements pointing to attachments as RPA, RPA is the most appropriate classification for the announcement itself. If the attachment were provided, it might be SHA or DIRS, but as a standalone announcement, RPA fits the 'MENU VS MEAL' rule.
2023-07-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.